SynthesisBMC infectious diseases2026
Valve involvement in infective endocarditis among intravenous drug users: a systematic review and meta-analysis.
Synthesis in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIntravenous drug use (IVDU) is a major risk factor for infective endocarditis (IE), with right-sided infective endocarditis (RSIE) most frequently observed. However, precise estimates of valve involvement and the relative risk (RR) of RSIE within the IVDU population remain unclear. This systematic review and meta-analysis aimed to quantify the prevalence of RSIE, left-sided IE (LSIE), both-sided IE, and valve-specific involvement in IVDUs while assessing the relative risk of right-sided versus left-sided IE within the IVDU population.
methodsA systematic search was conducted in PubMed, Embase, and Web of Science to identify studies reporting IE in IVDUs. Inclusion criteria followed the PICO framework, ensuring clear definitions of IVDU status and valve involvement. A random-effects model was used to calculate pooled prevalence estimates and RR ratios with 95% confidence intervals (CIs). Heterogeneity was assessed using the I² statistic, and sensitivity analyses were performed.
resultsA total of 14 studies involving 1,783 patients met the inclusion criteria. The pooled prevalence of right-sided infective endocarditis (RSIE) was 59% (95% CI: 54%-65%), left-sided infective endocarditis (LSIE) was 39% (95% CI: 33%-46%), and both-sided infective endocarditis was 8% (95% CI: 6%-12%). Among individual valves, the tricuspid valve was most commonly affected (59% (95% CI: 53%-64%)), followed by the mitral valve (21% (95% CI: 18%-26%)) and the aortic valve (16% (95% CI: 12%-20%)). Pulmonic valve involvement was rare (1% (95% CI: 0%-3%)). Overall, individuals who inject drugs (IVDUs) had a 1.49-fold increased risk of developing right-sided IE compared to left-sided IE (RR = 1.49 (95% CI: 1.15-1.95), p = 0.008).
conclusionThis SRMA confirms the predominance of right-sided IE, particularly tricuspid valve involvement, in IVDUs, with a significantly higher risk compared to left-sided IE. The findings underscore the need for targeted screening, early intervention, and IVDU-specific management strategies in IE care. Future research should focus on regional variations, microbiological patterns, and long-term outcomes in this high-risk population. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.